

Small Interfering RNA (siRNA) Therapeutics Market - 2024-2033

<https://marketpublishers.com/r/SFC60F8C10C6EN.html>

Date: August 2025

Pages: 219

Price: US\$ 2,999.00 (Single User License)

ID: SFC60F8C10C6EN

Abstracts

The Small Interfering RNA (siRNA) Therapeutics Market was valued at US\$ 2.55 billion in 2024 and is anticipated to reach US\$ 12.38 billion by 2033, at a CAGR of 0.174 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Small Interfering RNA (siRNA) Therapeutics Market.

This report delivers a comprehensive overview of the Small Interfering RNA (siRNA) Therapeutics Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Small Interfering RNA (siRNA) Therapeutics Market. The Small Interfering RNA (siRNA) Therapeutics Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

Small Interfering RNA (siRNA) Therapeutics Market Scope:

Major Highlights

This report delivers a comprehensive overview of the Small Interfering RNA (siRNA)

Therapeutics Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Small Interfering RNA (siRNA) Therapeutics Market. The Small Interfering RNA (siRNA) Therapeutics Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. MARKET INTRODUCTION AND SCOPE

- 1.1. Objectives of the Report
- 1.2. Report Coverage & Definitions
- 1.3. Report Scope

2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS

3. MARKET HIGHLIGHTS AND STRATEGIC TAKEAWAYS

- 3.1. Key Trends and Future Projections

4. SNIPPET BY DRUG

- 4.1. Snippet by Indication
- 4.2. Snippet by Route of Administration

5. SNIPPET BY REGION

6. DYNAMICS

- 6.1. Impacting Factors
 - 6.1.1. Drivers
 - 6.1.1.1. Rising R&D Activities and Product Approvals

7. RISING DEMAND FOR PERSONALIZED MEDICINE

8. RESTRAINTS

- 8.1. High Cost of Approved siRNA Therapies

9. OPPORTUNITIES

- 9.1. Expanding Applications of siRNA Therapies
 - 9.1.1. Impact Analysis

10. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK

- 10.1. Market Leaders and Pioneers
- 10.2. Latest Developments and Breakthroughs
- 10.3. Pipeline Analysis
- 10.4. Regulatory and Reimbursement Landscape
- 10.5. Pricing Analysis
- 10.6. Porter's Five Forces Analysis
- 10.7. Patent Analysis
- 10.8. SWOT Analysis
- 10.9. Unmet Needs and Gaps
- 10.10. Recommended Strategies for Market Entry and Expansion
- 10.11. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts

11. GLOBAL SMALL INTERFERING RNA (SIRNA) THERAPEUTICS MARKET, BY DRUG

- 11.1. Introduction
 - 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
 - 11.1.2. Market Attractiveness Index, By Drug
- 11.2. Patisiran*
 - 11.2.1. Introduction
 - 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 11.3. Givosiran
- 11.4. Lumasiran
- 11.5. Inclisiran
- 11.6. Nedosiran
- 11.7. Vutrisiran
- 11.8. Others

12. GLOBAL SMALL INTERFERING RNA (SIRNA) THERAPEUTICS MARKET, BY INDICATION

- 12.1. Introduction
 - 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
 - 12.1.2. Market Attractiveness Index, By Indication
- 12.2. Transthyretin Amyloidosis*
 - 12.2.1. Introduction
 - 12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

- 12.3. Acute Hepatic Porphyria
- 12.4. Primary Hyperoxaluria Type
- 12.5. Primary Hyperlipidemia
- 12.6. Others

13. GLOBAL SMALL INTERFERING RNA (SIRNA) THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION

- 13.1. Introduction
 - 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
 - 13.1.2. Market Attractiveness Index, By Route of Administration
- 13.2. Intravenous*
 - 13.2.1. Introduction
 - 13.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 13.3. Subcutaneous

14. GLOBAL SMALL INTERFERING RNA (SIRNA) THERAPEUTICS MARKET, BY REGION

- 14.1. Introduction
 - 14.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
 - 14.1.2. Market Attractiveness Index, By Region
- 14.2. North America
 - 14.2.1. Introduction
 - 14.2.2. Key Region-Specific Dynamics
 - 14.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
 - 14.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
 - 14.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
 - 14.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 14.2.6.1. U.S.
 - 14.2.6.2. Canada
 - 14.2.6.3. Mexico
- 14.3. Europe
 - 14.3.1. Introduction
 - 14.3.2. Key Region-Specific Dynamics
 - 14.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
 - 14.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication

14.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

14.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

14.3.6.1. Germany

14.3.6.2. U.K.

14.3.6.3. France

14.3.6.4. Spain

14.3.6.5. Italy

14.3.6.6. Rest of Europe

14.4. South America

14.4.1. Introduction

14.4.2. Key Region-Specific Dynamics

14.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug

14.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication

14.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

14.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

14.4.6.1. Brazil

14.4.6.2. Argentina

14.4.6.3. Rest of South America

14.5. Asia-Pacific

14.5.1. Introduction

14.5.2. Key Region-Specific Dynamics

14.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug

14.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication

14.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

14.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

14.5.6.1. China

14.5.6.2. India

14.5.6.3. Japan

14.5.6.4. South Korea

14.5.6.5. Rest of Asia-Pacific

14.6. Middle East and Africa

14.6.1. Introduction

14.6.2. Key Region-Specific Dynamics

14.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug

14.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication

14.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

15. COMPETITIVE LANDSCAPE AND MARKET POSITIONING

- 15.1. Competitive Overview and Key Market Players
- 15.2. Market Share Analysis and Positioning Matrix
- 15.3. Strategic Partnerships, Mergers & Acquisitions
- 15.4. Key Developments in Product Portfolios and Innovations
- 15.5. Company Benchmarking

16. COMPANY PROFILES

Key Market Players

1. ALNYLAM PHARMACEUTICALS, INC.*

- 1.1. Company Overview
 - 1.1.1. Product Portfolio
 - 1.1.1.1. Product Description
 - 1.1.1.2. Product Key Performance Indicators (KPIs)
 - 1.1.1.3. Historic and Forecasted Product Sales
 - 1.1.1.4. Product Sales Volume
 - 1.1.2. Financial Overview
 - 1.1.2.1. Company Revenue's
 - 1.1.2.2. Geographical Revenue Shares
 - 1.1.2.3. Revenue Forecasts
 - 1.1.3. Key Developments
 - 1.1.3.1. Mergers & Acquisitions
 - 1.1.3.2. Key Product Development Activities
 - 1.1.3.3. Regulatory Approvals, etc.
 - 1.1.4. SWOT Analysis
- 1.2. Novartis AG
- 1.3. Novo Nordisk A/S.THE LIST IS NOT EXHAUSTIVE

2. APPENDIX

- 2.1. About Us and Services
- 2.2. Contact Us

I would like to order

Product name: Small Interfering RNA (siRNA) Therapeutics Market - 2024-2033

Product link: <https://marketpublishers.com/r/SFC60F8C10C6EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/SFC60F8C10C6EN.html>